- Home
- FOLD vs CSQ Comparison
FOLD vs CSQ Comparison
Compare FOLD & CSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- CSQ
- Stock Information
- Founded
- FOLD 2002
- CSQ 2003
- Country
- FOLD United States
- CSQ United States
- Employees
- FOLD N/A
- CSQ N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- CSQ Finance Companies
- Sector
- FOLD Health Care
- CSQ Finance
- Exchange
- FOLD Nasdaq
- CSQ Nasdaq
- Market Cap
- FOLD 2.9B
- CSQ 2.7B
- IPO Year
- FOLD 2007
- CSQ N/A
- Fundamental
- Price
- FOLD $8.43
- CSQ $16.27
- Analyst Decision
- FOLD Strong Buy
- CSQ
- Analyst Count
- FOLD 9
- CSQ 0
- Target Price
- FOLD $17.00
- CSQ N/A
- AVG Volume (30 Days)
- FOLD 2.6M
- CSQ 220.3K
- Earning Date
- FOLD 05-08-2025
- CSQ 01-01-0001
- Dividend Yield
- FOLD N/A
- CSQ 7.53%
- EPS Growth
- FOLD N/A
- CSQ N/A
- EPS
- FOLD N/A
- CSQ N/A
- Revenue
- FOLD $528,294,999.00
- CSQ N/A
- Revenue This Year
- FOLD $21.91
- CSQ N/A
- Revenue Next Year
- FOLD $22.22
- CSQ N/A
- P/E Ratio
- FOLD N/A
- CSQ N/A
- Revenue Growth
- FOLD 32.29
- CSQ N/A
- 52 Week Low
- FOLD $8.36
- CSQ $12.50
- 52 Week High
- FOLD $12.65
- CSQ $16.45
- Technical
- Relative Strength Index (RSI)
- FOLD 35.37
- CSQ 36.37
- Support Level
- FOLD $8.40
- CSQ $16.10
- Resistance Level
- FOLD $9.26
- CSQ $16.98
- Average True Range (ATR)
- FOLD 0.25
- CSQ 0.29
- MACD
- FOLD -0.04
- CSQ 0.05
- Stochastic Oscillator
- FOLD 7.78
- CSQ 32.38
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.